Drug Profile
Cedirogant - AbbVie
Alternative Names: ABB-157; ABBV 157; ABV-157Latest Information Update: 23 May 2023
Price :
$50
*
At a glance
- Originator Inventiva Pharma
- Developer AbbVie
- Class Acetic acids; Antipsoriatics; Chlorobenzenes; Fluorinated hydrocarbons; Indoles; Piperidines; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders; Plaque psoriasis
Most Recent Events
- 11 May 2023 Efficacy, safety and pharmacokinetics data from a phase Ib trial in Plaque psoriasis presented at the American Academy of Dermatology annual Meeting 2023
- 17 Mar 2023 pooled adverse events and pharmacokinetics data from a phase-I trial in Plaque psoriasis presented at the (full name of conference American Academy of Dermatology annual Meeting (AAD-2023)
- 31 Oct 2022 Discontinued - Phase-I for Liver disorders in USA (PO)